OralDosed ingredient Cosmetic cross-reference

Magnesium Trisilicate

CAS 14987-04-3

Magnesium Trisilicate (CAS 14987-04-3) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 31 adverse event associations.

SOURCE NLM DailyMed
Label records
0
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
31
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Magnesium Trisilicate
CAS Number
14987-04-3
UNII
FML8G1U0Y3
InChIKey
GXGAKHNRMVGRPK-UHFFFAOYSA-N
ChEMBL ID
CHEMBL2096633
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
dosed ingredientoral
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL2096633 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE DrugCentral 31 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Appendicolith 32 103.365 10074458
Blood phosphorus increased 31 91.585 10050196
Hyponatraemia 74 80.325 10021036
Appendicitis 33 75.253 10003011
Ventricular fibrillation 34 65.866 10047290
Cardiogenic shock 36 63.414 10007625
Vomiting 131 55.61 10047700
Myasthenia gravis 21 52.628 10028417
Blood uric acid increased 22 50.374 10005861
Mesothelioma 10 47.582 10027406
Abdominal distension 48 46.553 10000060
Drug ineffective 18 39.482 10013709
Multiple organ dysfunction syndrome 41 36.871 10077361
Dry mouth 37 36.03 10013781
Hepatic cytolysis 21 34.731 10049199
Stress 34 34.383 10042209
Ascites 32 32.706 10003445
General physical health deterioration 61 31.788 10049438
Violence-related symptom 8 31.77 10047426
Abdominal pain 72 29.036 10000081
Exposure during pregnancy 42 28.933 10073513
Maternal drugs affecting foetus 12 23.42 10026923
Hyperphosphataemia 10 22.965 10020711
Morbid thoughts 6 22.718 10050464
IVth nerve paresis 3 21.18 10054201
Caesarean section 13 20.632 10006924
Coma scale abnormal 10 20.064 10069709
Iron deficiency 11 19.485 10022970
Fatigue 25 19.439 10016256
Hypophosphataemia 13 18.374 10021058
Hypertriglyceridaemia 11 18.109 10020869

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 2 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
MAGNESIUM TRISILICATE 29170 SU MTHSPL
magnesium trisilicate 29170 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Magnesium Trisilicate used for in pharmaceutical contexts?

Magnesium Trisilicate (CAS 14987-04-3) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Magnesium Trisilicate?

Magnesium Trisilicate has 31 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Appendicolith, Blood phosphorus increased, Hyponatraemia, Appendicitis, Ventricular fibrillation. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Magnesium Trisilicate also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Magnesium Trisilicate with EU status "permitted".

What clinical phase is Magnesium Trisilicate in?

Magnesium Trisilicate is rendered with ChEMBL max phase 4 (approved).